Reference SummaryMukherjee M, PLoS One 2011;6(7):e22167

Title

Separase Loss of Function Cooperates with the Loss of p53 in the Initiation and Progression of T- and B-Cell Lymphoma, Leukemia and Aneuploidy in Mice.

Authors

Mukherjee M; Ge G; Zhang N; Huang E; Nakamura LV; Minor M; Fofanov V; Rao PH; Herron A; Pati D

Journal

PLoS One

Volume

6

Issue

7

Year

2011

Pages

e22167

Abstract

BACKGROUND: Cohesin protease Separase plays a key role in faithful segregation of sister chromatids by cleaving the cohesin complex at the metaphase to anaphase transition. Homozygous deletion of ESPL1 gene that encodes Separase protein results in embryonic lethality in mice and Separase overexpression lead to aneuploidy and tumorigenesis. However, the effect of Separase haploinsufficiency has not been thoroughly investigated. METHODOLOGY/PRINCIPAL FINDINGS: Here we examined the effect of ESPL1 heterozygosity using a hypomorphic mouse model that has reduced germline Separase activity. We report that while ESPL1 mutant (ESPL1 (+/hyp)) mice have a normal phenotype, in the absence of p53, these mice develop spontaneous T- and B-cell lymphomas, and leukemia with a significantly shortened latency as compared to p53 null mice. The ESPL1 hypomorphic, p53 heterozygous transgenic mice (ESPL1(+/hyp), p53(+/-)) also show a significantly reduced life span with an altered tumor spectrum of carcinomas and sarcomas compared to p53(+/-) mice alone. Furthermore, ESPL1(+/hyp), p53(-/-) mice display significantly higher levels of genetic instability and aneuploidy in normal cells, as indicated by the abnormal metaphase counts and SKY analysis of primary splenocytes. CONCLUSIONS/SIGNIFICANCE: Our results indicate that reduced levels of Separase act synergistically with loss of p53 in the initiation and progression of B- and T- cell lymphomas, which is aided by increased chromosomal missegregation and accumulation of genomic instability. ESPL1(+/hyp), p53(-/-) mice provide a new animal model for mechanistic study of aggressive lymphoma and also for preclinical evaluation of new agents for its therapy.

Links

J:174926 – MGI References
21799785 – National Library of Medicine/PubMed

Models

Strain Model Name Treatment Agent(s) Organ Affected Frequency Model Details
C57BL/6J-Espl1Gt(XL058)Byg/+ Trp53tm1Tyj Leukocyte - Lymphocyte leukemia Blood

observed

B6.129S2-Trp53tm1Tyj/J Leukocyte - Lymphocyte leukemia Liver

0

C57BL/6J Leukocyte - Lymphocyte lymphoma Leukocyte - Lymphocyte

observed

B6.129S2-Trp53tm1Tyj/J Leukocyte - Lymphocyte lymphoma Leukocyte - Lymphocyte

observed - 70

C57BL/6J-Espl1Gt(XL058)Byg/+ Trp53tm1Tyj/+ Leukocyte - Lymphocyte lymphoma Leukocyte - Lymphocyte

0

C57BL/6J-Espl1Gt(XL058)Byg/+ Leukocyte - Lymphocyte lymphoma Leukocyte - Lymphocyte

0

B6.129S2-Trp53tm1Tyj/J Leukocyte - Lymphocyte lymphoma Leukocyte - Lymphocyte

0

B6.129S2-Trp53tm1Tyj/J Leukocyte - Lymphocyte lymphoma Thymus

observed

B6.129S2-Trp53tm1Tyj/J Leukocyte - Lymphocyte lymphoma Liver

0

B6.129S2-Trp53tm1Tyj/J Leukocyte - Lymphocyte lymphoma Spleen

observed

B6.129S2-Trp53tm1Tyj/J Leukocyte - Lymphocyte lymphoma Lung

observed

B6.129S2-Trp53tm1Tyj/J Leukocyte - Lymphocyte lymphoma Kidney

0

B6.129S2-Trp53tm1Tyj/J Leukocyte - Lymphocyte lymphoma Intestine - Large Intestine - Colon

0

B6.129S2-Trp53tm1Tyj/J Leukocyte - Lymphocyte lymphoma Bone marrow

0

C57BL/6J-Espl1Gt(XL058)Byg/+ Trp53tm1Tyj Leukocyte - Lymphocyte lymphoma - mixed Leukocyte - Lymphocyte

86 - 100

C57BL/6J-Espl1Gt(XL058)Byg/+ Trp53tm1Tyj Leukocyte - Lymphocyte lymphoma - mixed Thymus

observed - 100

C57BL/6J-Espl1Gt(XL058)Byg/+ Trp53tm1Tyj Leukocyte - Lymphocyte lymphoma - mixed Bone marrow

observed

C57BL/6J-Espl1Gt(XL058)Byg/+ Trp53tm1Tyj Leukocyte - Lymphocyte lymphoma - mixed Spleen

observed

C57BL/6J-Espl1Gt(XL058)Byg/+ Trp53tm1Tyj Leukocyte - Lymphocyte lymphoma - mixed Liver

observed

C57BL/6J-Espl1Gt(XL058)Byg/+ Trp53tm1Tyj Leukocyte - Lymphocyte lymphoma - mixed Lung

observed

C57BL/6J-Espl1Gt(XL058)Byg/+ Trp53tm1Tyj Leukocyte - Lymphocyte lymphoma - mixed Kidney

0

C57BL/6J-Espl1Gt(XL058)Byg/+ Trp53tm1Tyj Leukocyte - Lymphocyte lymphoma - mixed Intestine - Large Intestine - Colon

observed

C57BL/6J Mesodermal cell/mesoblast sarcoma Mesodermal cell/mesoblast

5

C57BL/6J-Espl1Gt(XL058)Byg/+ Trp53tm1Tyj Mesodermal cell/mesoblast sarcoma Mesodermal cell/mesoblast

0

B6.129S2-Trp53tm1Tyj/J Mesodermal cell/mesoblast sarcoma Mesodermal cell/mesoblast

50

C57BL/6J-Espl1Gt(XL058)Byg/+ Trp53tm1Tyj/+ Mesodermal cell/mesoblast sarcoma Mesodermal cell/mesoblast

10

C57BL/6J-Espl1Gt(XL058)Byg/+ Mesodermal cell/mesoblast sarcoma Mesodermal cell/mesoblast

0

B6.129S2-Trp53tm1Tyj/J Mesodermal cell/mesoblast sarcoma Mesodermal cell/mesoblast

0

C57BL/6J-Espl1Gt(XL058)Byg/+ Trp53tm1Tyj/+ (Unspecified organ) carcinoma (Unspecified organ)

40 - 50

C57BL/6J-Espl1Gt(XL058)Byg/+ Trp53tm1Tyj (Unspecified organ) carcinoma (Unspecified organ)

9

B6.129S2-Trp53tm1Tyj/J (Unspecified organ) carcinoma (Unspecified organ)

0

C57BL/6J-Espl1Gt(XL058)Byg/+ (Unspecified organ) carcinoma (Unspecified organ)

0

B6.129S2-Trp53tm1Tyj/J (Unspecified organ) carcinoma (Unspecified organ)

0

C57BL/6J-Espl1Gt(XL058)Byg/+ (Unspecified organ) tumor (Unspecified organ)

0

C57BL/6J (Unspecified organ) tumor (Unspecified organ)

5

C57BL/6J-Espl1Gt(XL058)Byg/+ Trp53tm1Tyj/+ (Unspecified organ) tumor (Unspecified organ)

observed - 100

C57BL/6J-Espl1Gt(XL058)Byg/+ Trp53tm1Tyj (Unspecified organ) tumor (Unspecified organ)

100

B6.129S2-Trp53tm1Tyj/J (Unspecified organ) tumor (Unspecified organ)

100

B6.129S2-Trp53tm1Tyj/J (Unspecified organ) tumor (Unspecified organ)

52